{
    "organizations": [],
    "uuid": "d438b593ac9842519c1f656b4a8995bd47b96dde",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-invokana-demonstrates-renal-protec/brief-invokana-demonstrates-renal-protective-benefits-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease-idUSFWN1RP0N1",
    "ord_in_thread": 0,
    "title": "BRIEF-Invokana Demonstrates Renal Protective Benefits In Patients With Type 2 Diabetes Mellitus And Chronic Kidney Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - Johnson & Johnson:\n* INVOKANAÂ® (CANAGLIFLOZIN) DEMONSTRATED SIGNIFICANT RENAL PROTECTIVE BENEFITS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE\n* ANALYSIS SHOWING INVOKANA IMPROVED RENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES MELLITUS WITH/AT HIGH RISK FOR CV DISEASE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-12T20:25:00.000+03:00",
    "crawled": "2018-04-13T18:03:26.054+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "johnson",
        "johnson",
        "canagliflozin",
        "demonstrated",
        "significant",
        "renal",
        "protective",
        "benefit",
        "patient",
        "type",
        "diabetes",
        "mellitus",
        "chronic",
        "kidney",
        "disease",
        "analysis",
        "showing",
        "invokana",
        "improved",
        "renal",
        "outcome",
        "people",
        "type",
        "diabetes",
        "mellitus",
        "high",
        "risk",
        "cv",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}